A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
Cancers · 07.03.2024 · 16 (6) · 1079
DOI: 10.3390/cancers16061079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 07.03.2024. Verfasst von Hollis Viray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, LUNGevity Foundation, National Institutes of Health (NIH).
Abstract (Originalsprache)
Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in EGFR mutated non-small cell lung cancer (NSCLC) based on the results of the randomized FLAURA trial (ClinicalTrials.gov number NCT02296125). We performed a retrospective analysis of baseline characteristics and clinical outcomes in 56 real-world patients treated with osimertinib. In total, 45% of patients were determined to be FLAURA-eligible and 55% were FLAURA-ineligible based on the published inclusion/exclusion criteria of the aforementioned trial. For clinical outcomes, the median osimertinib time to treatment discontinuation (TTD) for all patients was 16.9 months (95% CI: 12.6–35.1), whereas the median TTD was 31.1 months (95% CI: 14.9–not reached) in the FLAURA-eligible cohort and the median TTD was 12.2 months (95% CI: 8.1–34.6 months) in the FLAURA-ineligible cohort. Re-biopsy at acquired resistance disclosed both on- and off-target mechanisms. The most common therapies following osimertinib included local therapies followed by post-progression osimertinib, platinum-doublet chemotherapy with or without osimertinib, and osimertinib combinatory targeted therapies. The median overall survival for all patients was 32.0 months (95% CI: 15.7–not reached), the median survival was not reached for the FLAURA-eligible cohort, and it was 16.5 months for the FLAURA-ineligible cohort. Our data support the use of osimertinib in real-word settings and highlight the need for designing registration trials that are more inclusive of patient/disease characteristics seen in routine clinical practice. It is yet to be determined if the use of evolving first-line EGFR inhibitor combination strategies (either platinum-doublet chemotherapy plus osimertinib or amivantamab plus lazertinib) will similarly translate from clinical trials to real-word settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
- Division of Hematology/Oncology, Department of Medicine, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
ORCID-Profile: Paul A VanderLaan, Susumu S Kobayashi, Daniel B Costa
Förderung
- NCI NIH HHS
- LUNGevity Foundation
- National Institutes of Health (NIH)
- LUNGevity EGFR Resisters
Zitieren
APA
Viray, H., Piper-Vallillo, A. J., Widick, P., Academia, E., Shea, M., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2024). A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers, 16(6), 1079. https://doi.org/10.3390/cancers16061079
Vancouver
Viray H, Piper-Vallillo AJ, Widick P, Academia E, Shea M, Rangachari D, et al. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice. Cancers. 2024;16(6):1079. doi:10.3390/cancers16061079
BibTeX
@article{Viray2024,
author = {Viray, Hollis and Piper-Vallillo, Andrew J and Widick, Page and Academia, Emmeline and Shea, Meghan and Rangachari, Deepa and VanderLaan, Paul A and Kobayashi, Susumu S and Costa, Daniel B},
title = {A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice},
journal = {Cancers},
year = {2024},
volume = {16},
number = {6},
pages = {1079},
doi = {10.3390/cancers16061079}
}
EUVIMED